Literature DB >> 21515051

Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.

Kurt G Pike1, Joanne V Allen, Peter W R Caulkett, David S Clarke, Craig S Donald, Mark L Fenwick, Keith M Johnson, Craig Johnstone, Darren McKerrecher, John W Rayner, Rolf P Walker, Ingrid Wilson.   

Abstract

The continued optimization of a series of glucokinase activators is described, including attempts to understand the interplay between molecular structure and the composite parameter of unbound clearance. These studies resulted in the discovery of a new scaffold for glucokinase activators and further exploration of this scaffold led to the identification of GKA60. GKA60 maintains an excellent balance of potency and physical properties whilst possessing a significantly different, but complimentary, pre-clinical pharmacokinetic profile compared with the previously disclosed compound GKA50.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515051     DOI: 10.1016/j.bmcl.2011.03.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  1 in total

1.  Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM.

Authors:  Kaapjoo Park; Byoung Moon Lee; Kwan Hoon Hyun; Taedong Han; Dong Hoon Lee; Hyun Ho Choi
Journal:  ACS Med Chem Lett       Date:  2015-01-14       Impact factor: 4.345

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.